Author

David Pugatch 1

1 AbbVie Inc.,Chicago,United States

EFFICACY OF UPADACITINIB AS AN INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS, WITH OR WITHOUT PREVIOUS TREATMENT FAILURE OF BIOLOGIC THERAPY: DATA FROM THE DOSE-RANGING PHASE 2B STUDY U-ACHIEVE

Remo Panaccione, Geert R. D'Haens, William Sandborn, Subrata Ghosh, Stefan Schreiber, Satoshi Tanida, Wen Zhou, Fabio Cataldi, David Pugatch, Bidan Huang, Wangang Xie, Peter Higgins

Efficacy of upadacitinib as an induction therapy in severe and refractory ulcerative colitis: sub-group analysis of the phase 2b study U-ACHIEVE

Geert R. D'Haens, James Lindsay, Edward Loftus, Wen Zhou, Fabio Cataldi, Wangang Xie, David Pugatch, Remo Panaccione

Long-term efficacy and safety of upadacitinib treatment in patients with Crohn´s disease: One-year results of the ongoing phase 2 CELEST open-label extension study

Geert R. D'Haens, Julian Panés, Edouard Louis, Qian Zhou, David Pugatch, John Liu, Ana P. Lacerda, Edward Loftus

MEASUREMENT OF ULCERATED AND AFFECTED SURFACE OF THE COLON MAY PROVIDE MORE INSIGHT INTO RESPONSE COMPARED TO ENDOSCOPIC MAYO SCORE - A POST HOC ANALYSIS

Neeraj Narula, Marco Daperno, Abdul-Aziz Alshahrani, David Liu, David Pugatch, Walter Reinisch

Item 1 - 4 / 4
1